SEOUL, South Korea / KUALA LUMPUR, Malaysia – GC Biopharma, a leading South Korean biopharmaceutical company, today announced its significant expansion into the Malaysian plasma derivatives market. The company has secured a landmark consignment manufacturing contract valued at at least $24 million (approximately 33 billion Korean Won) over a minimum of four years, with supply commencing next year. This strategic move follows the company's successful entry into the U.S. market with its plasma derivative 'Alyglo,' signaling a robust acceleration in GC Biopharma's global business growth.
Partnership with JAKEL Group's SISB and Competitive Bid Success
The agreement, made public on June 6, is a consignment manufacturing deal for plasma-derived products with Solid Intellectual SDN BHD (SISB), a subsidiary of Malaysia's prominent JAKEL Group. The JAKEL Group, a leading private enterprise primarily known for its diverse business interests including textiles, leverages SISB as its specialized pharmaceutical and medical device distribution arm.
This partnership marks a pivotal moment, as GC Biopharma and SISB jointly participated in, and won, a highly competitive bid for the Malaysian Ministry of Health’s plasma consignment processing project in March. This achievement is particularly significant because GC Biopharma is the first Asian company to be selected as the sole consignment operator for this crucial national healthcare initiative. This win also notably ends a nearly 15-year exclusive arrangement previously held by global pharmaceutical giant CSL, indicating a strategic shift in Malaysia's procurement approach.
Enhancing Malaysia's Healthcare Supply Chain
Under the terms of the contract, the Malaysian Ministry of Health will supply plasma collected through its National Blood Center to SISB. SISB will then facilitate the transportation of this raw material to GC Biopharma's state-of-the-art facilities. GC Biopharma will utilize this plasma to produce essential finished products, including Albumin and Immunoglobulin, before exporting them back to SISB for distribution within Malaysia.
These plasma-derived therapies are critical for a wide range of medical conditions. Albumin is vital for maintaining blood volume and pressure, often used in cases of severe burns, shock, and liver disease. Immunoglobulin is crucial for treating various immune deficiencies, autoimmune disorders, and neurological conditions, providing essential antibodies to patients with compromised immune systems.
Strategic Global Expansion for GC Biopharma
This Malaysian deal underscores GC Biopharma's ambitious global strategy in the high-demand plasma derivatives market. The company has been steadily strengthening its international presence, notably securing FDA approval for its immunoglobulin product, Alyglo, in the U.S. in December 2023, with initial exports commencing in July 2024. To ensure a stable and reliable supply chain for its growing global endeavors, GC Biopharma also strategically acquired ABO Holdings, a U.S.-based plasma collection company, in January 2025. With this acquisition, all six of ABO Holdings' plasma centers in the United States are now FDA-approved, providing a robust source of raw plasma for GC Biopharma's manufacturing.
Growth in the Malaysian Plasma Market
For Malaysia, this contract represents a significant step towards enhancing its healthcare independence and ensuring a stable supply of critical plasma-derived medicines. While Malaysia currently lacks a self-sufficient plasma fractionation system, its government is actively investing in strengthening healthcare infrastructure and providing policy support to bolster product stability and availability. The Malaysian Blood Plasma Market, valued at approximately $54.5 million in 2022, is projected to reach $99.4 million by 2030, exhibiting a Compound Annual Growth Rate (CAGR) of 7.8%. This growth is primarily driven by the increasing demand for plasma-derived therapies and advancements in medical technology within the country. This partnership is expected to help diversify Malaysia's supply chain and ensure essential treatments for its growing population.
Woo-jin Lee, head of GC Biopharma's Global Business Division, emphasized the company's commitment to international collaboration. "We will continue to strengthen our position in the global plasma fractionation market through strategic partnerships between countries," Lee stated, highlighting the long-term vision behind such international collaborations.
This landmark agreement not only solidifies GC Biopharma's position as a key player in the global plasma derivatives industry but also signifies a new era of international cooperation in vital healthcare supply chains, promising improved patient access to life-saving treatments in Malaysia.
[Copyright (c) Global Economic Times. All Rights Reserved.]
